Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04349098. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time and across regions of the world.
Study identification
- NCT ID
- NCT04349098
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2020 (Actual)
- Primary completion
- Oct 5, 2020 (Actual)
- Completion
- Oct 5, 2020 (Actual)
- Last update posted
- Jan 20, 2023
2020
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | — |
| Kaiser Permanente Oakland | Oakland | California | 94612 | — |
| UC Davis Health | Sacramento | California | 95817 | — |
| Kaiser Permanente Sacramento | Sacramento | California | 95825 | — |
| Kaiser Permanente San Francisco | San Francisco | California | 94115 | — |
| Miami Cancer Institute at Baptist Health | Miami | Florida | 33176 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Advocate Christ Medical Center | Oak Lawn | Illinois | 60453 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 64113 | — |
| Norton Healthcare | Louisville | Kentucky | 40202 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Karmanos | Detroit | Michigan | 48201 | — |
| Michigan Center of Medical Research | Farmington Hills | Michigan | 48336 | — |
| Michigan Center of Medical Research | Royal Oak | Michigan | 48073 | — |
| Columbia University | New York | New York | 10032 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Levine Cancer Institute-Atrium Health University City | Charlotte | North Carolina | 28204 | — |
| Lehigh Valley Hospital | Allentown | Pennsylvania | 18103 | — |
| Baylor Scott & White Dallas | Dallas | Texas | 75201 | — |
| MultiCare Institute for Research & Innovation (Puget Sound) | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04349098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2023 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.